A Randomized, Open-label Therapeutic Trial Evaluating the Efficacy and Safety of Neridronate (Nerixia) in the Treatment of Osteoporosis in Patients With Thalassemia Major and Severe Thalassemia Intermedia.
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Neridronic acid (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Jul 2012 Results published in the British Journal of Haematology.
- 11 Jun 2010 New trial record